Top View
- MM&M Takes a Detailed Look at Key Products in the Pipeline
- Current Status of Oblimersen (Bcl-2 Antisense) Therapy for Advanced Melanoma
- Nilotinib/Oxaliplatin 757 3
- Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives
- Tommann Til Ut at Man At
- Novel Agents for the Treatment of Chronic Lymphocytic Leukemia
- Open Full Page
- Noncoding RNA Therapeutics — Challenges and Potential Solutions
- The Anticancer Action of a Novel 1,2,4-Triazine Sulfonamide Derivative in Colon Cancer Cells
- Emerging Drugs for Prostate Cancer
- System-Level Analysis of Neuroblastoma Tumor–Initiating Cells Implicates AURKB As a Novel Drug Target for Neuroblastoma
- Orphan Drug Designation List
- Combination Strategies to Overcome Resistance to the BCL2 Inhibitor Venetoclax in Hematologic Malignancies Xiaoyan Yue†, Qingxiao Chen† and Jingsong He*
- Ibrutinib- Obinutuzumab Chlorambucil
- (12) Patent Application Publication (10) Pub. No.: US 2008/0171718A1 Brown (43) Pub
- Novel Systemic Therapies for Small Cell Lung Cancer
- WO 2012/170640 Al 13 December 2012 (13.12.2012) P O P C T
- Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
- A Phase II, Pharmacokinetic, and Biological Correlative Study of Oblimersen Sodium and Docetaxel in Patients with Hormone-Refractory Prostate Cancer Anthony W
- Sensitization of a Human Ovarian Cancer Cell Line to Temozolomide by Simultaneous Attenuation of the Bcl-2 Antiapoptotic Protein
- Aberrant Glucose Metabolism in Glioblastoma
- Targeted Therapy Against Bcl-2-Related Proteins in Breast Cancer Cells Manabu Emi1, Ryungsa Kim2, Kazuaki Tanabe1, Yoko Uchida1 and Tetsuya Toge1
- The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Can Sensitize Human Lymphoma to Cyclophosphamide
- Antitumor Efficacy of Oblimersen Bcl-2 Antisense Oligonucleotide Alone and in Combination with Vinorelbine in Xenograft Models of Human Non–Small Cell Lung Cancer
- Efficient Inhibition of B-Cell Lymphoma Xenografts with a Novel
- Finally, an Apoptosis-Targeting Therapeutic for Cancer Carlo M
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
- Medicines & Vaccines in Development for Cancer
- Drug Allergy
- Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration
- London, 26 April 2007 Doc.Ref.: EMEA/451272/2007 REFUSAL CHMP ASSESSMENT REPORT for GENASENSE International Nonproprietary Name
- Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
- Branimir I. (Brandy) Sikic, M.D
- 1203 GVHD Prophylaxis, Version 3.0 Clean
- Apoptosis Signaling and BCL-2 Pathways Provide Opportunities for Novel T Targeted Therapeutic Strategies in Hematologic Malignances
- Oblimersen Sodium (Genasense, G3139) and Iri- As and Other Neoplastic Disorders
- Cell-Centric View of Apoptosis and Apoptotic Cell Death-Inducing Antitumoral Strategies
- Portals of Discovery
- Basic Science Summer Research Titles